DE69927960D1 - Epiallopregnanolon zur behandlung von krankheiten des cns - Google Patents

Epiallopregnanolon zur behandlung von krankheiten des cns

Info

Publication number
DE69927960D1
DE69927960D1 DE69927960T DE69927960T DE69927960D1 DE 69927960 D1 DE69927960 D1 DE 69927960D1 DE 69927960 T DE69927960 T DE 69927960T DE 69927960 T DE69927960 T DE 69927960T DE 69927960 D1 DE69927960 D1 DE 69927960D1
Authority
DE
Germany
Prior art keywords
epiallopregnanolone
treatment
cns
diseases
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927960T
Other languages
English (en)
Other versions
DE69927960T2 (de
Inventor
Torbjoern Backstroem
Ming-De Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine Mood AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69927960D1 publication Critical patent/DE69927960D1/de
Application granted granted Critical
Publication of DE69927960T2 publication Critical patent/DE69927960T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69927960T 1998-03-11 1999-03-10 Epiallopregnanolon zur behandlung von krankheiten des cns Expired - Lifetime DE69927960T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3786998A 1998-03-11 1998-03-11
US37869 1998-03-11
PCT/EP1999/001496 WO1999045931A1 (en) 1998-03-11 1999-03-10 Epiallopregnanolone in the treatment of cns disorders

Publications (2)

Publication Number Publication Date
DE69927960D1 true DE69927960D1 (de) 2005-12-01
DE69927960T2 DE69927960T2 (de) 2006-07-20

Family

ID=21896803

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927960T Expired - Lifetime DE69927960T2 (de) 1998-03-11 1999-03-10 Epiallopregnanolon zur behandlung von krankheiten des cns

Country Status (9)

Country Link
US (1) US6455516B1 (de)
EP (1) EP1063999B1 (de)
JP (1) JP3877961B2 (de)
CN (1) CN1270718C (de)
AT (1) ATE307592T1 (de)
AU (1) AU756001B2 (de)
CA (1) CA2321728C (de)
DE (1) DE69927960T2 (de)
WO (1) WO1999045931A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
BRPI0518359A2 (pt) 2004-11-18 2008-11-18 Umecrine Ab antagonistas de gaba-esteràide e seu uso para tratamento de distérbios do snc
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
SI2097437T1 (sl) 2006-11-21 2015-10-30 Umecrine Cognition Ab Uporaba pregnanskih in androstanskih steroidov za izdelavo farmacevtskega sestavka za zdravljenje obolenj ožs-ja
WO2008154579A1 (en) * 2007-06-11 2008-12-18 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
HUE027298T2 (en) * 2010-01-14 2016-10-28 Asarina Pharma Ab Pharmaceutical composition containing developed storage and dissolution properties containing 3-beta-hydroxy-5-alpha-pregnan-20-one
PT2709631T (pt) 2011-05-20 2017-04-19 Inserm - Inst Nat De La Santé Et De La Rech Médicale Antagonistas de receptor de cb1
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN112472814A (zh) 2012-01-23 2021-03-12 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经***障碍的方法
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
CA2892347C (en) 2012-11-28 2019-04-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JP6543633B2 (ja) 2014-01-29 2019-07-10 ウメクライン コグニション アーベー 肝性脳症の治療において使用するためのステロイド化合物
US10774108B2 (en) * 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
EP3565528A1 (de) * 2017-01-09 2019-11-13 Asarina Pharma AB Injizierbare suspensionen
CA3049954A1 (en) * 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
EP3579842A4 (de) 2017-02-10 2020-12-23 Asarina Pharma AB 3-beta-hydroxy-5-alpha-pregnan-20-on zur verwendung bei der behandlung von essentiellem tremor
WO2019075362A1 (en) * 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
US20210161915A1 (en) 2018-04-05 2021-06-03 Asarina Pharma Aps Gaba-a antagonists for treating substance withdrawal disorders
CN115806579A (zh) 2021-09-14 2023-03-17 南京迈诺威医药科技有限公司 一种水溶性别孕烷醇酮衍生物及其制备方法和用途
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU7569194A (en) * 1993-08-20 1995-03-21 Meyer B. Jackson Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
HUT77087A (hu) * 1994-11-23 1998-03-02 Cocensys Inc. Gaba A-receptor módosítására alkalmas androsztán- és pregnánvegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
WO1998050042A1 (en) * 1997-05-02 1998-11-12 American Home Products Corporation Pregnan-3-ol-20-ones

Also Published As

Publication number Publication date
CA2321728A1 (en) 1999-09-16
US6455516B1 (en) 2002-09-24
DE69927960T2 (de) 2006-07-20
ATE307592T1 (de) 2005-11-15
CN1270718C (zh) 2006-08-23
EP1063999B1 (de) 2005-10-26
CA2321728C (en) 2008-12-09
AU3329299A (en) 1999-09-27
AU756001B2 (en) 2003-01-02
JP3877961B2 (ja) 2007-02-07
EP1063999A1 (de) 2001-01-03
WO1999045931A1 (en) 1999-09-16
CN1300219A (zh) 2001-06-20
JP2002506034A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
DE69927960D1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
ATE350364T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
ATE311371T1 (de) Nicht-peptide inhibitoren von vla-4 abhängiger zellbindung für die behandlung von entzündungen, autoimmune krankheiten und atemstörungen
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
HUP0003852A2 (hu) Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE60139466D1 (de) Behandlung von diabetes
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
TR200003356T2 (tr) Kabergolin ve pramipeksol: yeni kullanım biçimleri ve birlikte kullanılmaları.
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
TR200200278T2 (tr) Kalsilitik bileşimler
HUP0001644A2 (hu) Eljárás kitinázok előállítására

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UMECRINE MOOD AB, STOCKHOLM, SE